Asset
Sonavibart
Vir Biotechnology Inc. Common Stock
Revenue
No revenue reported in loaded filings.
Clinical trials (2)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT05567783 | phase2 | terminated | 2022-10-30 | 2023-05-05 | Vir Biotechnology, Inc. | A Phase 2 Study to Evaluate the Efficacy and Safety of VIR-2482 for the Prevention of Illness Due to Influenza A |
| NCT04033406 | phase1 | completed | 2019-08-26 | 2021-11-01 | Vir Biotechnology, Inc. | Study of VIR-2482 in Healthy Volunteers |
FDA applications (0)
This company has no applications containing this asset.